Literature DB >> 17328580

Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium.

Torbjörn Tomson1, Dina Battino.   

Abstract

The treatment of epilepsy in pregnancy is particularly challenging in that the fetal and maternal risks associated with maternal seizures need to be balanced against the potential teratogenic effects of antiepileptic drugs (AEDs). Pregnancy is known to affect the pharmacokinetics of older-generation AEDs. Understanding such alterations is important in the effort to optimise drug therapy since they may affect seizure control as well as fetal drug exposure. Therapeutic drug monitoring has therefore been recommended to control for changes in the disposition of the older-generation AEDs during pregnancy. Much less is known about gestation-induced alterations in the pharmacokinetics of the newer AEDs that have been introduced in the last 15 years. Lamotrigine is by far the most extensively studied of the newer AEDs. Pronounced alterations have been reported in the apparent clearance of lamotrigine, with an increase of >300% from baseline in late pregnancy in some patients on monotherapy, most likely due to enhanced metabolism. The available data suggest that the corresponding decline in plasma concentrations can be associated with loss of seizure control. More limited data indicate that a similar decline in plasma concentrations of the active monohydroxy derivative of oxcarbazepine may occur in late pregnancy. Preliminary experience also suggests that a significant fall in plasma concentrations of levetiracetam may occur during pregnancy. No systematic information is available on the pharmacokinetics during pregnancy of other newer AEDs (e.g. gabapentin, pregabalin, tiagabine, topiramate or zonisamide). Given the importance of maintaining optimal treatment of epilepsy during pregnancy, therapeutic drug monitoring appears to be justified for lamotrigine and oxcarbazepine in particular. Systematic studies of the effects of pregnancy on the pharmacokinetics of the other newer-generation AEDs are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17328580     DOI: 10.2165/00003088-200746030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  56 in total

1.  Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.

Authors:  Z Hussein; J Posner
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

Review 2.  Plasma protein binding of drugs in pregnancy.

Authors:  E Perucca; A Crema
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

3.  Carbamazepine protein binding and disposition in pregnancy.

Authors:  M S Yerby; P N Friel; D Q Miller
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

4.  Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy.

Authors:  I Bernus; W D Hooper; R G Dickinson; M J Eadie
Journal:  Epilepsy Res       Date:  1995-05       Impact factor: 3.045

5.  The 10,11-epoxide-10,11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy.

Authors:  J G Omtzigt; F J Los; J W Meijer; D Lindhout
Journal:  Ther Drug Monit       Date:  1993-02       Impact factor: 3.681

6.  Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.

Authors:  Torbjörn Tomson; Emilio Perucca; Dina Battino
Journal:  Epilepsia       Date:  2004-10       Impact factor: 5.864

7.  Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.

Authors:  Iolanda Mazzucchelli; Filiz Yilmaz Onat; Cigdem Ozkara; Dilek Atakli; Luigi M Specchio; Angela La Neve; Giuliana Gatti; Emilio Perucca
Journal:  Epilepsia       Date:  2006-03       Impact factor: 5.864

Review 8.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications.

Authors:  Javier Adín; M Cruz Gómez; Yolanda Blanco; José L Herranz; Juan A Armijo
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

10.  Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women.

Authors:  D Rating; H Nau; E Jäger-Roman; I Göpfert-Geyer; S Koch; G Beck-Mannagetta; D Schmidt; H Helge
Journal:  Acta Paediatr Scand       Date:  1982-03
View more
  18 in total

Review 1.  Epilepsy in pregnancy.

Authors:  Torbjörn Tomson; Vilho Hiilesmaa
Journal:  BMJ       Date:  2007-10-13

Review 2.  Management of epilepsy during pregnancy: an update.

Authors:  Sima I Patel; Page B Pennell
Journal:  Ther Adv Neurol Disord       Date:  2015-12-27       Impact factor: 6.570

Review 3.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 4.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

5.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

Review 6.  Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?

Authors:  Page B Pennell
Journal:  Epilepsia       Date:  2008-12       Impact factor: 5.864

Review 7.  Long-term consequences after exposure to antiepileptic drugs in utero.

Authors:  Lisa Forsberg; Katarina Wide
Journal:  Ther Adv Drug Saf       Date:  2011-10

Review 8.  Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts.

Authors:  Page B Pennell
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 9.  Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Authors:  Matthieu Roustit; Malik Jlaiel; Pascale Leclercq; Françoise Stanke-Labesque
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335

Review 10.  Pregnancy, epilepsy, and anticonvulsants.

Authors:  Bernhard J Steinhoff
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.